Perma-Pipe International Holdings showed significant improvement in its Q2-2026 results compared to last year, supported by growing demand for engineered systems in district heating and cooling. The company benefits from recurring revenue through multi-year service agreements and is expanding its presence in the Middle East. These factors contribute to a positive outlook, with a maintained Strong Buy rating and a target price range of $37.41 to $84.20 over the next year, reflecting strong execution and favorable market trends.
Perma-Pipe International Holdings is the story's subject, with Pluang market data providing context. For readers following Industrials, here is Pluang's market snapshot as of Sep 15, 2026 23:21 WIB: 22 of 75 priced US Industrials stocks rose, 52 fell. Notable prices include GXO at USD 46.04 (-1.90%), LUV at USD 38.89 (-1.59%), and FDX at USD 307.63 (-1.58%).
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
